Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Centrexion Therapeutics announced a successful raise of $40.5 million through convertible security investments from Lilly and Exome Asset Management, along with expanded lending from Solar Capital Partners. This capital will bolster Centrexion's pipeline of four clinical-stage drug candidates targeting chronic pain, including therapies in Phase 3 and Phase 2a trials. With over $75 million in cash post-fundraise, the company plans further in-licensing of promising mid-stage assets. The ongoing collaboration with Lilly further validates Centrexion's strategy in the pain management sector.